// App-Quantinova.ai

6036 : Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.

Researchers

Presenter

  • Kevin Joseph Harrington

Principal Investigators

  • Anthony Kong

  • Nicolas Mach

  • Jason Alan Chesney

  • Beatriz Castelo

  • Danny Rischin

  • Ezra E.W. Cohen

  • Hoi-Shen Radcliffe

  • Burak Gumuscu

  • Wendy Snyder

  • Lillian L. Siu

Medical Centers

  • The Royal Marsden//The Institute of Cancer Research NIHR Biomedical Research Centre, London, United Kingdom

  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom

  • Department of Ophthalmology, University Hospitals of Geneva, Geneva, Switzerland

  • Brown Cancer Center, University of Louisville, Louisville, KY, Department of Medical Oncology, La Paz University Hospital, Madrid, Spain

  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Australia, Victoria, Australia

  • University of California, San Diego, La Jolla, CA

  • Amgen, Ltd., Uxbridge, United Kingdom

  • Merck & Co., Inc., Kenilworth, NJ, Amgen, Inc., Thousand Oaks, CA

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

Locations

  • United Kingdom

  • Switzerland

  • Spain

  • Australia

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • N/A

Drug/Treatment

  • Imlygic

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • I

Study Id's

  • NCT02626000

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved